BCLSI
REPL icon

Bain Capital Life Sciences Investors’s Replimune Group REPL Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,122,415
Closed -$48.9M – 27
2020
Q3 		$48.9M Sell
2,122,415
-40,183
-2% -$916K 4.55% 6
2020
Q2 		$53.7M Sell
2,162,598
-676,370
-24% -$12M 5.63% 6
2020
Q1 		$28.3M Hold
2,838,968
– – 4.79% 6
2019
Q4 		$40.7M Hold
2,838,968
– – 6.08% 5
2019
Q3 		$39.5M Hold
2,838,968
– – 10.16% 4
2019
Q2 		$41.6M Hold
2,838,968
– – 21.14% 2
2019
Q1 		$43.2M Hold
2,838,968
– – 17.28% 2
2018
Q4 		$28.4M Hold
2,838,968
– – 9.7% 5
2018
Q3 		$45.7M Buy
+2,838,968
New +$49.8M 10.37% 5

Other funds holding REPL

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bain Capital Life Sciences Investors's REPL Position: Q4 2020 in Review

Bain Capital Life Sciences Investors sold out of Replimune Group (REPL) in Q4 2020, closing a stake of 2,122,415 shares — an estimated $48.9M sold.

Bain Capital Life Sciences Investors first reported a position in REPL in Q3 2018 and held it in 9 quarters. The position peaked at $53.7M in Q2 2020. 112 funds tracked by Wall St. Rank hold REPL as of Q4 2020.

  • Bain Capital Life Sciences Investors reported no remaining Replimune Group position as of Q4 2020 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 2,122,415 Replimune Group shares in Q4 2020, an estimated $48.9M.
  • Bain Capital Life Sciences Investors first reported a position in Replimune Group in Q3 2018 and held it in 9 quarters.
  • Bain Capital Life Sciences Investors's Replimune Group position peaked at $53.7M in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Replimune Group as of Q4 2020.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2020, filed 16 Feb 2021.